Pharmaceutic preparation of losartan potassium

Abstract

The invention provides a pharmaceutic preparation of iosartan potassium, comprising losartan potassium, lactose, microcrystalline cellulose, calcium hydrophosphate and lauryl sodium sulfate, and prepared by the wet granulation technology. The pharmaceutic preparation has the advantage that high hydroscopicity of iosartan potassium can be improved, and the mixed materials have good flowability. Besides, the pharmaceutic preparation has high dissolution rate and good stability.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a losartan potassium pharmaceutical preparation and a preparation method of the pharmaceutical preparation. Background technique [0002] Hypertension is the most important risk factor leading to the occurrence and death of heart disease, cerebrovascular disease, and kidney disease. The purpose of antihypertensive drug therapy for hypertensive patients is to effectively prevent or delay stroke, myocardial infarction, The occurrence of cardiovascular and cerebrovascular complications such as heart failure and renal insufficiency can effectively control the disease process of hypertension and prevent the occurrence of severe hypertension such as hypertensive emergencies and sub-emergencies. [0003] Losartan potassium, also known as 2-butyl-4-chloro-1-([2'-(1H-tetrazole-5)(1,1''-biphenyl)-4-yl]methyl) -1H-imidazole-5-methanol monopotassium salt, is a new type of non-p...

AI Technical Summary

Problems solved by technology

[0005] Losartan potassium has the characteristics of strong water absorption and sensitivity to water. During the preparation process, the viscosity of the material is too large, which makes it difficult to prepare drug granules. The prepared losartan potassium preparation has the problem of unstable storage quality under high humidity conditions.

[0006] CN201110250254.5 discloses a method of wet granulation, the main preparation steps of which are to prepare blank granules first, and then mix the main drug losartan potassium and lubricant magnesium stearate with the blank granules. Magnesium fatty acid and the main drug Losartan Potassium are mixed evenly with other components, and an equal-volume incremental mixing method is adopted. Although this method achieves the purpose of mixing evenly, the long mixing process not only affects the preparation efficiency , It is also very easy to cause excessive mixing of magnesium stearate and losartan potassium to affect the dissolution of losartan potassium, thereby affecting the efficacy

Images